# Department of Defense Fiscal Year (FY) 2014 President's Budget Submission

April 2013



## Defense Advanced Research Projects Agency

Justification Book Volume 1 of 1

Research, Development, Test & Evaluation, Defense-Wide

xhibit R-2A, RDT&E Project Justification: PB 2014 Defense Advanced Research Projects Agency			April 2013	
APPROPRIATION/BUDGET ACTIVITY         R-1 ITEM NOMENCLATURE         PRO           0400: Research, Development, Test & Evaluation, Defense-Wide         PE 0601101E: DEFENSE RESEARCH         BLS           BA 1: Basic Research         SCIENCES         SCIENCES         BLS			MICRO SCIE	ENCES
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2012	FY 2013	FY 2014
<ul> <li>Demonstrated the utility of new compressive measurement theory via i <i>FY 2013 Plans:</i></li> <li>Identify fundamental bounds on performance and cost associated with</li> <li>Demonstrate novel reconstruction algorithms that incorporate both sign quality and/or reduced measurement resources.</li> <li>Demonstrate visible imaging using 10x fewer measurements than reco</li> <li>Demonstrate RADAR imaging using 10x less bandwidth than a conven</li> <li>Exploit the benefit of adaptation in order to achieve additional reductior</li> <li>Exploit the benefit of information-optimal measurements within a signal</li> </ul>	linear and nonlinear signal priors. nal and task priors to enable improved reconstruction nstructed pixels. tional non-compressive system. ns in performance and/or measurement resources.	n		
<ul> <li>FY 2014 Plans:</li> <li>Demonstrate hyperspectral imaging using 100x fewer measurements to</li> <li>Explore application of compressive sensing concepts to alternate sensional investigate the potential gains available from compressive sensing with</li> <li>Leverage advances in neuroscience and neurological measurements to learning, and neuro-physiologic recovery.</li> </ul>	ing modalities such as X-ray imaging. iin a video application.	9.450		
<ul> <li>Title: Physics in Biology</li> <li>Description: Understanding the fundamental physical phenomena that underlie biological processes and functions will provide new insight and unique opportunities for understanding biological properties and exploiting such phenomena. Physics in biology will explore the role and impact of quantum effects in biological processes and systems. This includes exploiting manifestly quantum mechanical effects that exist in biological systems at room temperature to develop a revolutionary new class of robust, compact, high sensitivity and high selectivity sensors. Finally, the quantum phenomena uncovered will be exploited to control the attraction of insects to humans with the potential to completely eliminate insect bites and thus the transmission of parasitic, bacterial or viral pathogens.</li> <li>FY 2012 Accomplishments: <ul> <li>Developed theory and performed simulations for the transduction of the magnetoreception signal on the visual field.</li> <li>Developed a general theory for photosynthetic transport, governed by a single parameter, that shows that it is an example of a quantum 'Goldilocks effect', i.e., the degree of quantum complexity and coherence is 'just right' for attaining maximum efficiency.</li> <li>Formulated a new concept of "excitonic circuits" (that concentrate and direct excitons as in photosynthesis) and designed generic circuit elements.</li> </ul> </li> </ul>			7.678	7.500

Exhibit R-2A, RDT&E Project Justification: PB 2014 Defense Advance	ed Research Projects Agency		DATE:	April 2013		
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 1: Basic Research	R-1 ITEM NOMENCLATURE PE 0601101E: DEFENSE RESEARCH SCIENCES		PROJECT BLS-01: BIO/INFO/MICRO SCIENCES			
B. Accomplishments/Planned Programs (\$ in Millions)		[	FY 2012	FY 2013	FY 2014	
<ul> <li>Verified that molecular vibrations, and thus quantum effects, are essen</li> <li>FY 2013 Plans:</li> </ul>	ntial to describing olfaction.					
<ul> <li>Develop prototype synthetic sensors that utilize biologically inspired queen period of the ability to control quantum effects in biological system mechanism using radio frequency fields.</li> <li>Demonstrate the biological and evolutionary advantage of quantum effects.</li> </ul>	s by reorienting magnetoreception through the radi	cal pair				
<ul> <li>FY 2014 Plans:</li> <li>Demonstrate prototype quantum biological sensors against their equivisensitivity, selectivity and other performance metrics.</li> <li>Explore quantum physics-based mechanisms of mosquito bio-sensing vector-born disease protection against diseases such as malaria or denoted the sense of the sense</li></ul>	related to mosquito attraction to humans for novel,					
	30.463	39.678	29.771			
N/A <u>Remarks</u> <u>D. Acquisition Strategy</u> N/A <u>E. Performance Metrics</u> Specific programmatic performance metrics are listed above in the pro	gram accomplishments and plans section.					
PE 0601101E: DEFENSE RESEARCH SCIENCES	UNCLASSIFIED			· · · · ·		

Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency			April 2013	
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 1: Basic Research	R-1 ITEM NOMENCLATURE PE 0601117E: BASIC OPERATIONAL MEDICAL	SCIENCE		
C. Accomplishments/Planned Programs (\$ in Millions)		FY 2012	FY 2013	FY 2014
<ul> <li>Develop models that predict the evolution of neural firing patterns neural connections aimed at facilitating recovery.</li> </ul>	following brain injury, and following the introduction of artificia	1		
<ul> <li>FY 2014 Plans:</li> <li>Demonstrate the ability of non-human primates to perform a dexter without the use of neural spike recordings.</li> <li>Develop new methods of analysis and interpretation for measuring reconstruction.</li> <li>Develop novel technologies, such as optical/non-optical tools and group of cells in the tissues and organs of a living organism in a nor</li> <li>Develop methods of data analysis and interpretation that will allow cellular processes in situ.</li> </ul>	g brain tissue alterations without the need for image cellular dyes, to detect the functional dynamics of a cell or a n-invasive manner.			
Title: Autonomous Diagnostics to Enable Prevention and Therapeu	19.511	24.500	40.500	
<b>Description:</b> The Autonomous Diagnostics to Enable Prevention ar technologies to rapidly respond to a disease or threat and improve in providing capabilities, which are currently available only in centralize settings. ADEPT will develop and exploit synthetic biology for the in and autonomously sense and respond to changes in physiologic sta- immunogenicity, or control activity of vaccines, potentially eliminatin advancements to control cellular machinery include research to opti- identify methods to increase sensitivity and specificity; and demonst changes in physiological status. ADEPT will develop methodologies biospecimen to enable diagnostics at the point-of-need or resource Additionally, ADEPT will develop techniques that will enable the rap the production of components of the immune system to impart effect bridge the time gap between the delivery of a vaccine and the devel research efforts are budgeted in PE 0602115E, Project BT-01.	individual readiness and total force health protection by ed laboratories in the U.S., to non-tertiary care and individual n vivo creation of nucleic acid circuits that continuously ate and for novel methods to target delivery, enhance ag the time to manufacture a vaccine ex vivo. ADEPT imize orthogonality and modularity of genetic control elements trate methods to control cellular machinery in response to s for measuring health-specific biomarkers from a collected limited clinical facilities (point-of-care), in-garrison or deployed bid establishment of transient immunity through stimulation of ctive but temporary protection. This transient immunity would			
<ul> <li>FY 2012 Accomplishments:</li> <li>Initiated development of modular and orthogonal nucleic acid-bas operating within the context of a mammalian cell.</li> <li>Investigated controlled expression in mammalian cells of synthetic with health status.</li> <li>Developed novel concepts and molecular approaches to enable of the context of a mammalian cells of the context of a mammalian cells of the context of a mammalian cells.</li> </ul>	c circuit that responds to physiological biomarkers associated			
PE 0601117E: BASIC OPERATIONAL MEDICAL SCIENCE Defense Advanced Research Projects Agency	UNCLASSIFIED Page 3 of 6 R-1 Line #4		V	olume 1 - 51

0400: Research, Development, Test & Evaluation, Defense-Wide BA 1: Basic Research C. Accomplishments/Planned Programs (\$ in Millions) - Developed novel reagents and materials for stabilizing self-collected biospeci and storage.	R-1 ITEM NOMENCLATURE PE 0601117E: BASIC OPERATIONAL MEDICAL SC	EVENCE		
- Developed novel reagents and materials for stabilizing self-collected biospeci and storage.				
and storage.				
<ul> <li>Developed methods for sample preparation that require no operator manipula point-of-care settings.</li> <li>Developed new methods for signal amplification amenable to deployable diag</li> <li>Investigated the ability of administered synthetic oligonucleotides to direct cell</li> </ul>	ation and are consistent with point-of-need and gnostics.			
<ul> <li>FY 2013 Plans: <ul> <li>Demonstrate development of modular and orthogonal nucleic acid-based elercircuit that operates within the context of a mammalian cell.</li> <li>Demonstrate controlled expression in mammalian cells of synthetic circuit that with health status.</li> <li>Quantify sensitivity and specificity of developed molecular approaches design concentrations of clinically relevant analytes in complex biospecimens.</li> <li>Quantify performance of biostabilization reagents/materials to evaluate analyte compared to traditional stabilization methods that require cold-chain storage.</li> <li>Quantify performance of methods for room temperature analyses and reagent similar-to-enhanced performance as compared to current laboratory methods for</li> <li>Quantify detection limits achieved with signal amplification methods to demon art methods for quantification of low abundance biomarkers in an actionable time.</li> <li>Demonstrate performance of new sample preparation methods suitable for sim that are either self-collected under low-resource settings or collected by trained</li> <li>Design integration of developed diagnostic methodologies.</li> <li>Quantify the level of antibody and immunoadhesin production directed by the comparison to standard vaccine delivery.</li> <li>Investigate the impact of the antibody sequence on the therapeutic strength of FY 2014 Plans:</li> <li>Demonstrate in mammalian cells the function of a synthetic circuit that can int status and respond with a targeted change in cell function.</li> <li>Demonstrate the ability to generate synthetic nucleic acid and protein circuit or supplied small molecule drug trigger.</li> </ul> </li> </ul>	at responds to physiological biomarkers associated need for deployable diagnostics using physiological tical recovery of clinically relevant molecules as at stabilization to demonstrate analytical results with or clinical diagnostics. Instrate performance superior to current state of the heframe. Imple and multiplexed analysis of biospecimens professionals at the physician-office settings. I administration of synthetic oligonucleotides in of immune response in vivo. Itegrate multiple signals associated with health components that respond to an exogenously			

Defense Advanced Research Projects Agency

Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency			DATE: April 2013			
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 1: Basic Research	R-1 ITEM NOMENCLATURE PE 0601117E: BASIC OPERATIONAL MEDICAL S	SCIENCE				
C. Accomplishments/Planned Programs (\$ in Millions)			FY 2013	FY 2014		
<ul> <li>Demonstrate biostabilization reagents/materials with numerous biospect eventually integrated into disposable and on-person diagnostic devices.</li> <li>Demonstrate methods for room temperature analyses and reagent state approaches to permit collection and transport of patient samples for diagnetic developed sample preparation methods in conjunction with processing a prostrate developed sample preparation methods in conjunction with representative of those either self-collected under low-resource settings to assist the diagnosis of an individual.</li> <li>Demonstrate delivery of synthetic oligonucleotide constructs to cells appendicted antibody and immunoadhesin production targeted to spece optimize antibody sequence for maximal therapeutic strength of immunoadhesing the settings of the settings.</li> </ul>	pilization with numerous biospecimen types and fluidic nostic analysis. ng/assay methods. It simple and multiplexed analysis of biospecimens or collected by trained professionals at the physician- propriate to produce an antibody response. cific disease classes.					
Title: Dialysis-Like Therapeutics			5.000	0.00		
<b>Description:</b> Sepsis, a bacterial infection of the blood stream, is a signification of this program is to develop a portable device capable volume on clinically relevant time scales. Reaching this goal is expected biologic fluids, complex fluid manipulation, separation of components from of providing predictive control over the closed loop process. The envision patients each year by effectively treating sepsis and associated complication will be the development of non-fouling continuous sensors for comparatures that do not require the use of anticoagulation; development of pathogen specific molecular labels or binding chemistries; and predictive sufficient fidelity to enable agile adaptive closed-loop therapy. Applied re BT-01.	e of controlling relevant components in the blood to require significant advances in sensing in complex in these fluids, and mathematical descriptions capable ned device would save the lives of thousands of military tions. imately make up the integrated device. Included in this blex biological fluids; design of high-flow microfluidic intrinsic separation technologies that do not require modeling and control (mathematical formalism) with search efforts are budgeted in PE 0602115E, Project					
<ul> <li>Achieved detection over 10 days of ricin toxin B chain in whole blood us substrate functionalized with degradation-resistant aptamers.</li> <li>Flowed whole blood at 3 L/hr for 60 minutes without clotting in specially</li> <li>Removed &gt; 80% of pathogens and inflammatory molecules from flowin</li> <li>Improved the outcome of 7x more virtual patients as compared to static</li> <li>FY 2013 Plans:</li> </ul>	functionalized medical tubing. g blood using label-free separation technologies.					

PE 0601117E: BASIC OPERATIONAL MEDICAL SCIENCE Defense Advanced Research Projects Agency

### DATE: April 2013 Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency APPROPRIATION/BUDGET ACTIVITY **R-1 ITEM NOMENCLATURE** 0400: Research, Development, Test & Evaluation, Defense-Wide PE 0601117E: BASIC OPERATIONAL MEDICAL SCIENCE BA 1: Basic Research C. Accomplishments/Planned Programs (\$ in Millions) FY 2012 FY 2013 FY 2014 - Improve sensing technologies to achieve continuous detection of pathogens and biomolecules in flowing blood, blood components, and wound fluid. - Refine microfluidic architectures and coatings for continuous blood flow without platelet activation or clotting. - Enhance label-free separation technologies to successfully remove pathogens and select bioagents from blood or blood components. Validate the sepsis predictive modeling using data from small animal testing within the program. Accomplishments/Planned Programs Subtotals 44,445 39.676 49.500 D. Other Program Funding Summary (\$ in Millions) N/A Remarks E. Acquisition Strategy N/A F. Performance Metrics Specific programmatic performance metrics are listed above in the program accomplishments and plans section. UNCLASSIFIED PE 0601117E: BASIC OPERATIONAL MEDICAL SCIENCE

Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency		DATE: April 2013		
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 2: Applied Research	R-1 ITEM NOMENCLATURE PE 0602115E: BIOMEDICAL TECHNOLOGY			
C. Accomplishments/Planned Programs (\$ in Millions)	FY 2012	FY 2013	FY 2014	
<ul> <li>Develop a platform to reproducibly demonstrate the evolutionary pathwe</li> <li>Validate algorithms' abilities to predict viral evolution in the presence of</li> <li>Predict timing, location(s) and nature of genetic mutation(s) responsible model.</li> <li>Predict number of viral generations necessary for the acquisition of ant</li> <li>Predict location of genetic mutation(s) responsible for failure of a mono</li> <li>Correlate influenza vaccine failure in syngeneic/specific pathogen-free of Asia.</li> <li>Use in vitro evolution reactors to predict emergence of novel, variant in predict emergence of dengue virus mutations in a region where dengue letter of the predict of the invitro evolution of the pathogen of the region of the predict of the predict of the predict of the predict emergence of dengue virus mutations in a region where dengue letter of the predict emergence of the predict emergence of the predict emergence of</li></ul>	f one or multiple pressures. e for antiviral failure in an infected viral host (animal) tiviral resistance in an infected viral host (animal) model. oclonal antibody to neutralize a virus. poultry with pathogen evolution in the natural ecologies afluenza strains from within-reservoir species, and to has recently appeared.	ii.		
FY 2014 Plans: - Demonstrate that the in vitro bioreactor can be used to predict alteration - Validate viral evolution platforms and predictive platforms with a live fine - Transition predictive algorithms and in vitro evolution platforms to the C government agencies to increase preparedness for seasonal influenza as - Transition predictive algorithms and in vitro evolution platforms to the p drug-resistant strains of commercially relevant viruses.	e test. Center for Disease Control (CDC) and other interested s well as other emerging pathogens.			
Title: Autonomous Diagnostics to Enable Prevention and Therapeutics (A	ADEPT)	11.169	15.000	29.85
<b>Description:</b> The overarching goal of the Autonomous Diagnostics to Entropy to increase our ability to rapidly respond to a disease or threat and improviding centralized laboratory capabilities at non-tertiary care setting Acid (RNA)-based vaccines, potentially eliminating the time and labor reconstructions and time improving efficacy. ADEPT will also focus on advanced developments. A companion basic research effort is budgeted in PE 0601117E	we individual readiness and total force health protection gs. ADEPT will focus on the development of Ribonucleic quired for traditional manufacture of a vaccine while at the lopment of key elements for simple-to-operate diagnostic			
<ul> <li>FY 2012 Accomplishments:</li> <li>Increased stability of RNA-based vaccines.</li> <li>Demonstrated efficacy of RNA-based vaccines in a small animal mode</li> <li>Demonstrated sample preparation methods designed for integration in in reusable diagnostics that can be used at the point-of-care.</li> </ul>				
PE 0602115E: BIOMEDICAL TECHNOLOGY	UNCLASSIFIED			

Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Adv	vanced Research Projects Agency	DATE:	April 2013	
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 2: Applied Research	R-1 ITEM NOMENCLATURE PE 0602115E: BIOMEDICAL TECHNOLOGY			
C. Accomplishments/Planned Programs (\$ in Millions)	(	FY 2012	FY 2013	FY 2014
<ul> <li>Developed high sensitivity colorimetric and electrical detection approa autonomous diagnostics that will be deployed as either on-person device</li> </ul>				
FY 2013 Plans: - Demonstrate increased humoral and cellular responses with RNA-bas - Demonstrate increased efficacy of RNA-based vaccines in vivo in sma - Demonstrate quantitative performance metrics for device components components) to enable diagnostic device capabilities in the remote-clinic	all and large animal models. (sample preparation/reagent delivery/detection			
<ul> <li>FY 2014 Plans:</li> <li>Demonstrate quantitative performance metrics for integrated compone complete diagnostic device prototype.</li> <li>Demonstrate ability to manipulate type of immune response induced b</li> <li>Demonstrate ability to target delivery of RNA-based vaccines to specified to the performance of the performance</li></ul>	by RNA-based vaccines. fic cell types. ing one or hundreds of antibodies identified from			
Title: Tactical Biomedical Technologies		18.223	15.500	13.32
<b>Description:</b> The Tactical Biomedical Technologies thrust will develop in the battlefield. Uncontrolled blood loss is the leading cause of prevental control of hemorrhage is the most effective strategy for treating combate surgical intervention can effectively treat intracavitary bleeding. A focus agent(s) and delivery mechanism capable of damaged tissue-targeted in treat compressible and non-compressible wounds regardless of geomet biological threats on the battlefield is impacted by logistical delays of del on demand" will enable far-forward medical providers to manufacture an ensure that the therapeutics are available when they need them. Anoth in real time who represent depression and suicide risk by identifying spe algorithms, protocols, and methods to allow registration and comparison experimental systems, hierarchies and populations).	ble death for soldiers on the battlefield. While immediate casualties and saving lives, currently no method other than in this thrust is the co-development of a materials-based nemostasis and wound control. This system will effectively ry or location. Additionally, rapid response to emerging livering the necessary therapeutics. Creating a "pharmacy and produce small molecule drugs and biologics in order to er effort will develop assessment tools to identify soldiers eech biomarkers. This project will also develop new			
FY 2012 Accomplishments: - Demonstrated hemostasis agent stability consistent with operational re-	equirements.			
PE 0602115E: BIOMEDICAL TECHNOLOGY	UNCLASSIFIED			olume 1 - 58
Defense Advanced Research Projects Agency	Page 4 of 14 R-1 Line #9		V	101110 1 - 30

#### DATE: April 2013 Exhibit R-2. RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency APPROPRIATION/BUDGET ACTIVITY **R-1 ITEM NOMENCLATURE** 0400: Research, Development, Test & Evaluation, Defense-Wide PE 0602115E: BIOMEDICAL TECHNOLOGY BA 2: Applied Research C. Accomplishments/Planned Programs (\$ in Millions) FY 2012 FY 2013 FY 2014 Investigate options for broadband nuclear magnetic resonance detection for the simultaneous acquisition of multiple nuclear species. FY 2014 Plans: Design a compact prototype device for performing novel MRI-like imaging and spectroscopy using quantum orbital resonance spectroscopy (QORS) in military medical environments. - Obtain neurochemical spectra using QORS technique. Title: Dialysis-Like Therapeutics 5.000 10,000 20.000 Description: Sepsis, a bacterial infection of the blood stream, is a significant cause of injury and death among combat-injured soldiers. The goal of this program is to develop a portable device capable of controlling relevant components in the blood volume on clinically relevant time scales. Reaching this goal is expected to require significant advances in sensing in complex biologic fluids, complex fluid manipulation, separation of components from these fluids, and mathematical descriptions capable of providing predictive control over the closed loop process. The envisioned device would save the lives of thousands of military patients each year by effectively treating sepsis and associated complications. Applied research under this program further develops and applies existing component technologies and then integrates these to create a complete blood purification system for use in the treatment of sepsis. Included in this effort will be development, integration and demonstration of non-fouling, continuous sensors for complex biological fluids; implementation of high-flow microfluidic structures that do not require the use of anticoagulation; application of intrinsic separation technologies that do not require pathogen specific molecular labels or binding chemistries; and refinement of predictive modeling and control (mathematical formalism) with sufficient fidelity to enable agile adaptive closed-loop therapy. The basic research part of this program is budgeted in PE 0601117E, Project MED-01. FY 2012 Accomplishments: Evaluated existing sensing, microfluidic flow, and intrinsic separation component technologies for use in an integrated blood purification system and initiated research plan to achieve significant improvements in line with the overall program goals. Initiated integration plan for component technologies developed in the basic research aspect of this program. Identified a regulatory pathway leading to an approved integrated device. FY 2013 Plans: Refine integration strategy, develop a bread-board system, and demonstrate bread-board system. Develop appropriate animal models, confirm regulatory plan, and begin regulatory approval process for the integrated device. FY 2014 Plans:

UNCLASSIFIED

PE 0602115E: BIOMEDICAL TECHNOLOGY Defense Advanced Research Projects Agency

Volume 1 - 61

Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Adv.	anced Research Projects Agency	DATE:	April 2013	
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 2: Applied Research	R-1 ITEM NOMENCLATURE PE 0602115E: BIOMEDICAL TECHNOLOGY			
C. Accomplishments/Planned Programs (\$ in Millions)		FY 2012	FY 2013	FY 2014
<ul> <li>Integrate continuous sensing, biocompatible high-flow fluid manipulation modeling and control in a prototype device for the treatment of sepsis.</li> <li>Use feedback from initial animal model testing to inform the development studies in a large animal model.</li> <li>Continue regulatory approval process and initiate plan for investigation.</li> </ul>	ent of a prototype device for additional safety and efficacy			
Title: Warrior Web		0.000	10.750	12.000
<ul> <li>Description: Musculoskeletal injury and fatigue to the warfighter caused immediate mission readiness, but also can have a deleterious effect on the program will mitigate that impact by developing an adaptive, quasi-active current soldier systems. Because this sub-system will be compliant and sustained by warfighters while allowing them to maintain performance. of component technologies in areas such as regenerative kinetic energy performance, system, and component modeling; novel materials and dyr and power distribution/energy storage. The final suit is planned to weigh external power. Allowing the warfighter to perform their missions with remission readiness, soldier survivability, mission performance and the long funded in the Maintaining Combat Performance Thrust in PE 0602715E,</li> <li>FY 2013 Plans:</li> <li>Complete injury assessment and component technology integration integrated to meet Warrior Web performance requirements.</li> </ul>	the warfighter throughout his/her life. The Warrior Web e, joint support sub-system that can be integrated into be transparent to the user, it will reduce the injuries Success in this program will require the integration harvesting to offset power/energy demands; human namic stiffness; actuation; controls and human interface; in no more than 9kg and require no more than 100W of educed risk for injuries will have immediate effects on ng-term health of our veterans. This effort was previously Project MBT-02.		-	
<ul> <li>FY 2014 Plans:</li> <li>Leverage open source biomechanical model to iterate design.</li> <li>Complete component technology based on results of Preliminary Designation into current soli</li> <li>Initiate design of full Warrior Web including integration into current soli</li> <li>Conduct Critical Design Review of full Warrior Web solider system control</li> </ul>	der system.			
Title: Revolutionizing Prosthetics*		0.000	17.000	10.000
Description: *Previously funded in PE 0602715E, Project MBT-02.				
PE 0602115E: BIOMEDICAL TECHNOLOGY	UNCLASSIFIED			olume 1 - 62

APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 2: Applied Research			R-1 ITEM NOMENCLATURE PE 0602715E: MATERIALS AND BIOLOGICAL TECHNOLOGY				DATE: April 2013 PROJECT MBT-02: BIOLOGICALLY BASED MATERIALS AND DEVICES			)		
COST (\$ in Millions)	All Prior Years	FY 2012	FY 2013"	FY 2014 Base	FY 2014 OCO **	FY 2014 Total	FY 2015	FY 2016	FY 2017	FY 2018	Cost To Complete	Total Cost
MBT-02: BIOLOGICALLY BASED MATERIALS AND DEVICES	-	47.379	37.623	40.301	-	40.301	50.976	64.357	55.085	55.835	Continuing	Continuin

\* FY 2013 Program is from the FY 2013 President's Budget, submitted February 2012

" The FY 2014 OCO Request will be submitted at a later date

#### A. Mission Description and Budget Item Justification

This project acknowledges the growing and pervasive influence of the biological sciences on the development of new DoD capabilities. This influence extends throughout the development of new materials, devices, and processes and relies on the integration of biological breakthroughs with those in engineering and the physical sciences. Contained in this project are thrusts in the application of biomimetic materials and devices for Defense, the use of biology's unique fabrication capabilities to produce structures that cannot be made any other way, the application of materials in biological applications, and the development of manufacturing tools that use biological components and processes for materials synthesis. This project also includes major efforts aimed at integrating biological and digital sensing methodologies and maintaining human combat performance despite the extraordinary stressors of combat. Finally, this thrust will develop new cognitive therapeutics, and explore neuroscience technologies.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2012	FY 2013	FY 2014
Title: Neuroscience Technologies	10.827	10.000	8.000
<b>Description:</b> The Neuroscience Technologies thrust leverages recent advances in neurophysiology, neuro-imaging, cognitive science, and molecular biology to sustain and protect the cognitive functioning of the warfighter faced with challenging operational conditions. Warfighters experience a wide variety of operational stressors, both mental and physical, that degrade critical cognitive functions such as memory, learning, and decision making. These stressors also degrade the warfighter's ability to multitask, leading to decreased ability to respond quickly and effectively. Currently, the long-term impact of these stressors on the brain is unknown, both at the molecular and behavioral level. This thrust area will utilize modern neuroscientific techniques, in conjunction with emerging solutions in neurally enabled human-machine interface technologies, to develop quantitative models of this impact and explore mechanisms to protect, maintain, complement, or restore cognitive functioning during and after exposure to operational stressors. In addition, new approaches for using neural signals to make human-machine systems more time efficient and less workload intense will be identified, developed, and evaluated. This thrust area will have far-reaching implications for both current and future military operations, with the potential to protect and improve cognitive performance at the individual and group level both prior to and during deployment.			

Exhibit R-2A, RDT&E Project Justification: PB 2014 Defense Advance	ced Research Projects Agency	DATE	April 2013		
APPROPRIATION/BUDGET ACTIVITY 0400: Research, Development, Test & Evaluation, Defense-Wide BA 2: Applied Research	R-1 ITEM NOMENCLATURE PE 0602715E: MATERIALS AND BIOLOGICAL TECHNOLOGY		JECT -02: BIOLOGICALLY BASED ERIALS AND DEVICES		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2012	FY 2013	FY 2014	
<ul> <li>Began reconstructing a multi-scale network linked to specific stressor epigenetics, genetics, quantitative model building, bioinformatics, and c</li> <li>Continued modeling and verification of causal factors and relationship involved in the response to stress and the ability to resist stress.</li> <li>Modulated genes and pathways mediating acute and chronic stress- learning for reduction of stress-related dysfunction in animal models.</li> <li>Developed and implemented interventions for prevention of stress- chronic stress.</li> <li>Expanded studies of stress-related dysfunction to include identifying grelates to suicide.</li> <li>Demonstrated quantitative biochemical measurement of the impact o biosensors.</li> </ul>	computational biology approaches. The complex systems and net induced dysfunction in circuits for reward, fear, and his duced cognitive dysfunction in animal models of acute gene, network and specific brain region dysfunction a	abit e and is it			
<ul> <li>FY 2013 Plans:</li> <li>Integrate human data on stress genes to determine human stress-reli-</li> <li>Translate genes and networks identified in animals to humans using I studies.</li> <li>Determine biomarkers of alertness in active duty personnel with psyci-</li> <li>Relate clinical and psychological profiles of patients with post-trauma behavior for biomarker identification.</li> <li>Develop empirically validated intervention strategies to include stress training/hyperrealistic training), and/or pharmacological interventions, w</li> <li>Identify objective measures of physical and cognitive states through t computational techniques.</li> </ul>	high throughput molecular data from population-base hological health problems/traumatic brain injury. tic stress disorder to neural networks, neurochemical reduction (exercise, meditation), stress inoculation ( hile maintaining performance.	s and			
FY 2014 Plans: - Determine genetic, epigenetic, and proteomic changes underlying vul - Exploit advances in the predictive models of the brain to develop tools under stress at both the individual and group level.		ance			
Title: BioDesign		6.791	11.023	14.084	
<b>Description:</b> BioDesign will employ system engineering methods in contechnology to create novel beneficial attributes. BioDesign mitigates the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance in the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses that increase resistance is the primarily by advanced genetic engineering and molecular biology technothrust area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primarily by advanced genetic engineering area includes designed molecular responses to the primari	e unpredictability of natural evolutionary advancement ologies to produce the intended biological effect. The	nt is			

PE 0602715E: MATERIALS AND BIOLOGICAL TECHNOLOGY Defense Advanced Research Projects Agency

#### DATE: April 2013 Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Defense Advanced Research Projects Agency APPROPRIATION/BUDGET ACTIVITY **R-1 ITEM NOMENCLATURE** 0400: Research, Development, Test & Evaluation, Defense-Wide PE 0602716E: ELECTRONICS TECHNOLOGY BA 2: Applied Research C. Accomplishments/Planned Programs (\$ in Millions) FY 2012 FY 2013 FY 2014 Demonstrate proof of concept of fundamental building blocks of intrachip thermal management including microfabrication in relevant electronic substrates and preliminary thermofluid results. Prepare and refine initial thermal models of intrachip cooling to explain and predict experimental results. Demonstrate benefits to system-level performance and size, weight, power, and cost (SWaPC) through the use of intrachip thermal management technologies. Title: In vivo Nanoplatforms (IVN) 5.000 18,500 0.000 Description: The In vivo Nanoplatforms (IVN) program seeks to develop the nanoscale systems necessary for in vivo sensing and physiologic monitoring and delivery vehicles for targeted biological therapeutics. The nanoscale components to be developed will enable continuous in vivo monitoring of both small (e.g. glucose, lactate, and urea) and large molecules (e.g. biological threat agents). A reprogrammable therapeutic platform will enable tailored therapeutic delivery to specific areas of the body (e.g. cells, tissue, compartments) in response to traditional, emergent, and engineered threats. The key challenges to developing these systems include safety, toxicity, biocompatibility, sensitivity, response, and targeted delivery. The IVN program will have diagnostic and therapeutic goals that enable a versatile, rapidly adaptable system to provide operational support to the warfighter in any location. FY 2013 Plans: Achieve a safe in vivo nanoplatform sensor to detect one military-relevant analyte (e.g. glucose) in living cells for one month. Achieve a safe in vivo nanoplatform therapeutic to reduce a military-relevant pathogen or disease cofactor in living cells by 50%. Facilitate development of a regulatory approval pathway for diagnostic and therapeutic nanoplatforms. FY 2014 Plans: Achieve a safe in vivo nanoplatform sensor to detect two military-relevant analytes (e.g. glucose, pathogen) in a small animal for six months. - Achieve a safe in vivo nanoplatform therapeutic to reduce a military-relevant pathogen or disease cofactor in a small animal by 70%. Begin to obtain regulatory approval of identified safe and effective diagnostic and therapeutic nanoplatforms. Title: Pixel Network (PIXNET) for Dynamic Visualization 15.000 22,700 0.000 Description: The Pixel Network for dynamic visualization (PIXNET) program addresses the squad level capability gap for target detection, recognition and identification in all weather and day/night missions. The vision of the program is to offer the warfighter a small and versatile infrared (IR) camera that would be affordable to individual soldiers and provide multiple IR band imagery with fusion capability to take full advantage of different wavelength band phenomenology in a compact single unit. In the future, the availability of the PIXNET camera would enable a peer-to-peer networked system for image sharing within a squad, thereby providing a better common operating picture of the battlefield and significantly enhancing the warfighter's situational

UNCLASSIFIED

PE 0602716E: ELECTRONICS TECHNOLOGY Defense Advanced Research Projects Agency